• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study.

作者信息

Lytvyn Yuliya, Mufti Asfandyar, Zaaroura Hiba, Sachdeva Muskaan, Lu Justin D, Rankin Brian D, Prajapati Vimal H, Vender Ronald, Yeung Jensen

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

JAAD Int. 2021 Nov 9;6:3-5. doi: 10.1016/j.jdin.2021.09.007. eCollection 2022 Mar.

DOI:10.1016/j.jdin.2021.09.007
PMID:34816136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8592884/
Abstract
摘要

相似文献

1
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study.临床实践中瑞莎珠单抗治疗中重度斑块状银屑病的疗效和安全性：一项为期16周的加拿大回顾性多中心队列研究。
JAAD Int. 2021 Nov 9;6:3-5. doi: 10.1016/j.jdin.2021.09.007. eCollection 2022 Mar.
2
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.
3
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.利斯库珠单抗与阿达木单抗治疗中重度斑块型银屑病患者的疗效比较（IMMvent）：一项随机、双盲、活性对照的 3 期临床试验。
Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4.
4
Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.里莎珠单抗与乌司奴单抗治疗斑块状银屑病：批判性评价。
Br J Dermatol. 2019 Jun;180(6):1348-1351. doi: 10.1111/bjd.17624. Epub 2019 Mar 27.
5
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.在中重度斑块型银屑病患者中，连续 risankizumab 治疗与停药治疗的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723.
6
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study.司库奇尤单抗在成人斑块状银屑病患者中的真实世界有效性和安全性：一项为期16周的国际多中心回顾性队列研究。
J Cutan Med Surg. 2024 Nov-Dec;28(6):604-605. doi: 10.1177/12034754241274300. Epub 2024 Sep 3.
7
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.在中度至重度斑块型银屑病日本患者中的疗效和安全性：来自 SustaIMM 2/3 期研究的结果。
J Dermatol. 2019 Aug;46(8):686-694. doi: 10.1111/1346-8138.14941. Epub 2019 Jun 25.
8
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.司库奇尤单抗治疗中度至重度慢性斑块状银屑病患者的长期安全性和有效性：一项2期开放标签扩展试验的结果
Dermatol Ther (Heidelb). 2021 Apr;11(2):487-497. doi: 10.1007/s13555-021-00490-3. Epub 2021 Jan 29.
9
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.利纳西珠单抗治疗中重度斑块状银屑病。
Ann Pharmacother. 2020 Apr;54(4):380-387. doi: 10.1177/1060028019885836. Epub 2019 Oct 31.
10
Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.司库奇尤单抗治疗中重度银屑病：来自捷克共和国的真实多中心经验。
Dermatol Ther (Heidelb). 2021 Aug;11(4):1345-1355. doi: 10.1007/s13555-021-00556-2. Epub 2021 Jun 5.

引用本文的文献

1
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database.司库奇尤单抗治疗银屑病和关节病型银屑病的药物警戒：来自欧洲药品管理局药物警戒数据库的真实世界数据
Pharmaceutics. 2023 Jul 11;15(7):1933. doi: 10.3390/pharmaceutics15071933.

本文引用的文献

1
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.司库奇尤单抗治疗银屑病有效性和安全性的多中心研究：意大利在新冠疫情期间的16周真实世界经验
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e169-e170. doi: 10.1111/jdv.17003. Epub 2020 Nov 8.
2
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.司库奇尤单抗与瑞莎珠单抗治疗中度至重度斑块状银屑病患者的疗效与安全性比较（IMMerge）：一项III期随机开放标签、疗效评估者设盲临床试验的结果
Br J Dermatol. 2021 Jan;184(1):50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6.
3
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.在中重度斑块型银屑病患者中，连续 risankizumab 治疗与停药治疗的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723.
4
Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.司库奇尤单抗和依奇珠单抗治疗中重度斑块型银屑病的药物生存情况。
J Am Acad Dermatol. 2019 Jul;81(1):173-178. doi: 10.1016/j.jaad.2019.03.048. Epub 2019 Mar 23.
5
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.在中重度斑块型银屑病中的疗效和安全性（UltIMMa-1 和 UltIMMa-2）：两项双盲、随机、安慰剂对照和乌司奴单抗对照的 3 期临床试验结果。
Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.